News from hyundai bioscience A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 25, 2022, 08:00 ET Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea's biotech firm

An innovative anticancer therapy that may complete chemotherapy with two doses of an anticancer drug in as short as 8 days is to enter a clinical...

May 25, 2022, 20:25 ET Hyundai Bioscience to request a fast track processing for its monkeypox treatment drug with the FDA

Hyundai Bioscience will go straight to the US with its broad-spectrum antiviral drug candidate to treat monkeypox. Hyundai Bioscience has decided to...

May 12, 2022, 06:19 ET A novel universal antiviral drug introduced in Korea

The birth of a universal antiviral drug with a mechanism applicable to all viral infections is approaching. This antiviral agent, developed in Korea, ...

Dec 07, 2021, 09:00 ET CP-COV03, a niclosamide-based oral antiviral drug, under study as possible cure for COVID-19 variants

SUMMARY CP-COV03, a niclosamide-based oral antiviral drug, to cure COVID-19 variants CP-COV03 is a broad-spectrum antiviral drug candidate, developed ...

May 23, 2021, 20:16 ET A 'Game Changer' COVID-19 drug from Korea was introduced in a world class academic journal

Hyundai Bioscience (KOSDAQ 048410) announced on the 24th that CNPharm, its major shareholding bio tech company, published an article containing the...

May 13, 2021, 04:37 ET An oral antiviral drug from Korea may be a problem solver for COVID-19

Hyundai Bioscience (KOSDAQ 048410) announced that Dr. Jin-Ho Choi, a Chief Scientist of its major shareholding bio tech company CNPharm and Chair...

Apr 19, 2021, 08:15 ET CNPharm has succeeded in maintaining IC100 for 24 hours with one injection

Hyundai Bioscience (Symbol 048410), a KOSDAQ listed company, announced on the 19th that its major shareholding bio tech company, CNPharm's single...

Apr 08, 2021, 05:17 ET Hyundai Bioscience leads in the repurposing of Niclosamide

A research paper by a South Korean bio tech company that demonstrated the drug repurposing of Niclosamide, an anthelmintic known to have excellent...

Dec 22, 2020, 21:09 ET Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19

Hyundai Bioscience (KOSDAQ symbol: 048410) announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded ...

Dec 08, 2020, 08:00 ET Hyundai Bioscience announced that its COVID-19 oral drug solved Niclosamide's inhibitory concentration problem

Hyundai Bioscience (KOSDAQ symbol: 048410) released a report on December 8th that CP-COV03, its new COVID-19 oral drug candidate, successfully...

Oct 29, 2020, 08:00 ET Hyundai Bioscience: A Korean bio-tech solves the bioavailability issue of Niclosamide

Expectations are increasing as a Korean bio-tech company has succeeded in solving the problem of low absorption which has been one of the biggest...

Jun 30, 2020, 03:10 ET 'Curing Cancer without Surgery'

There has been an increase in the possibility for the 'conquering of cancer' as test results confirm, for the first time, the disappearance of tumors ...

Jul 09, 2019, 09:00 ET Hyundai Bioscience Unveils New Cancer Treatment that Offers Tumor Elimination without Painful Side Effects

On June 28th, Hyundai Bioscience Co., Ltd., a KOSDAQ-listed company, released exciting efficacy results for its new 'NOAEL Cancer Therapy' at the...